{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-003889","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.438148+00:00","generated_at":"2026-05-23T16:29:03.457967+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MIRA receives Nasdaq minimum equity deficiency notice; equity $2.2M vs $2.5M","bullets":["Stockholders' equity $2,199,750 as of Dec 31, 2024, below Nasdaq's $2.5M minimum requirement under Rule 5550(b)(1).","Company has 45 days to submit a compliance plan by May 23, 2025; Nasdaq may grant up to 180-day extension.","Plans to complete SKNY Pharmaceuticals acquisition with $5M capital infusion to boost equity.","Also in discussions with strategic investors to strengthen capital position; trading continues uninterrupted.","Phase 1 trial of Ketamir-2 for neuropathic pain ongoing; first subject dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-003889","json":"https://secwatch.observer/filing/0001641172-25-003889.json","markdown":"https://secwatch.observer/filing/0001641172-25-003889.md","text":"https://secwatch.observer/filing/0001641172-25-003889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225003889/0001641172-25-003889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225003889/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T16:29:03.457967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a173e45441ca076c93c8c2fad28501c4f0a3cf43","claim":"MIRA PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 8, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff indicating that, based on the Company’s stockholders’ equity of $2,199,750 as of December 31, 2024, the Company does not currently meet the minimum stockholders’ equity requirement of $2.5 million as set forth under Nasdaq Listing Rule 5550(b)(1). Importantly, this notice does not affect the Company’s listing status or the trading of its common stock, which will continue uninterrupted on the Nasdaq Capital Market under the ticker symbol “MIRA.” In accordance with Nasdaq proc","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225003889/0001641172-25-003889-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}